Coloplast (COLO B) Aperçu de l'action
Coloplast A/S développe et vend des produits et des services de soins intimes au Danemark, aux États-Unis, au Royaume-Uni, en France et dans le monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 3/6 |
| Croissance future | 5/6 |
| Performances passées | 0/6 |
| Santé financière | 3/6 |
| Dividendes | 5/6 |
Récompenses
Analyse des risques
COLO B Community Fair Values
Create NarrativeSee what 55 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Coloplast A/S Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | DKK 435.80 |
| Plus haut sur 52 semaines | DKK 646.60 |
| Plus bas sur 52 semaines | DKK 369.70 |
| Bêta | 0.55 |
| Variation sur 1 mois | 5.24% |
| Variation sur 3 mois | 7.98% |
| Variation sur 1 an | -29.64% |
| Variation sur 3 ans | -45.47% |
| Variation sur 5 ans | -60.36% |
| Évolution depuis l'introduction en bourse | 3,310.61% |
Nouvelles et mises à jour récentes
Article d’analyse • 7h
Coloplast A/S Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
The quarterly results for Coloplast A/S ( CPH:COLO B ) were released last week, making it a good time to revisit its...
Mise à jour du récit • Aug 19
COLO B: Biologics And China Pressures Will Restrain Sentiment Despite Guidance
Coloplast's analyst fair value estimate has moved from DKK 345 to DKK 370, reflecting updated assumptions on discount rates, margins and future P/E in the context of recent mixed price target revisions from DKK 345 to DKK 460 by various analysts. Analyst Commentary Recent Street research on Coloplast shows a mix of cautious and more constructive views on the stock's valuation and execution risks.Recent updates
Article d’analyse • 7h
Coloplast A/S Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
The quarterly results for Coloplast A/S ( CPH:COLO B ) were released last week, making it a good time to revisit its...Mise à jour du récit • Aug 19
COLO B: Biologics And China Pressures Will Restrain Sentiment Despite Guidance
Coloplast's analyst fair value estimate has moved from DKK 345 to DKK 370, reflecting updated assumptions on discount rates, margins and future P/E in the context of recent mixed price target revisions from DKK 345 to DKK 460 by various analysts. Analyst Commentary Recent Street research on Coloplast shows a mix of cautious and more constructive views on the stock's valuation and execution risks.
Mise à jour du récit • Jul 15
COLO B: Recent P/E Reset Will Create Upside Opportunity
Analysts have lowered the fair value estimate for Coloplast to DKK 584 from DKK 868, reflecting a reset in price assumptions and P/E expectations, while recent price targets across the Street range from DKK 345 to DKK 484. Analyst Commentary Recent Street research on Coloplast shows a wide spread in views, but there are several constructive signals that point to ongoing interest in the stock at current levels.Mise à jour du récit • Jun 30
COLO B: Reset Expectations And New Products Will Shape Future Sentiment
The analyst price target for Coloplast has been revised from DKK 535 to DKK 345. This reflects a reset in valuation assumptions as analysts weigh recent target cuts against differing views on how the recent share selloff relates to company fundamentals and future P/E expectations.
Mise à jour du récit • Jun 16
COLO B: Recent Pullback And New FDA Approval Will Support Future Re Rating
The analyst price target for Coloplast has been revised slightly, with the updated fair value held around DKK 462 as analysts factor in a modestly lower discount rate and only small tweaks to growth and margin assumptions following a series of recent target cuts and one new Buy initiation around DKK 482. Analyst Commentary Recent research on Coloplast highlights a split in opinion, with some analysts seeing value after the share price pullback and others focusing on execution risk and margin pressure in their updated targets.Mise à jour du récit • Jun 02
COLO B: New CEO And Lower P/E Will Support Future Multiple Re Rating
The updated analyst price target for Coloplast moves from DKK 500.15 to DKK 461.90, as analysts factor in slightly firmer revenue growth assumptions, a small change in the discount rate, and a lower future P/E multiple, while recent research highlights both reduced targets and one new Buy initiation after the share selloff. Analyst Commentary Recent Street research on Coloplast reflects a mix of optimism and caution, with several firms adjusting price targets and ratings following the share selloff.Article d’analyse • May 20
Some May Be Optimistic About Coloplast's (CPH:COLO B) Earnings
Shareholders appeared unconcerned with Coloplast A/S' ( CPH:COLO B ) lackluster earnings report last week. Our analysis...Article d’analyse • May 15
Coloplast A/S Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next
Last week saw the newest half-year earnings release from Coloplast A/S ( CPH:COLO B ), an important milestone in the...Mise à jour du récit • May 10
COLO B: New CEO And Reset P/E Will Support Future Multiple Re Rating
The analyst price target on Coloplast has been reduced from DKK 551.68 to DKK 500.15, as analysts incorporate a series of recent target cuts and mixed ratings while adjusting assumptions around the discount rate, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Recent Street research on Coloplast has centered on a series of target cuts and rating changes that feed directly into the revised average price target.Mise à jour du récit • Apr 24
COLO B: New CEO Appointment Will Underpin Future Multiple Re Rating Potential
Coloplast's analyst price target has been nudged lower to about DKK 552 from roughly DKK 561, reflecting recent cuts to DKK-based targets by several banks as analysts factor in a slightly higher discount rate, a modestly adjusted future P/E assumption and only small tweaks to long term growth and margin expectations. Analyst Commentary Recent Street research around Coloplast has centered on recalibrated price targets and rating changes as analysts reassess what they are willing to pay for the company, given updated discount rates and P/E assumptions.Mise à jour du récit • Apr 09
COLO B: New CEO Appointment Will Support Future Re Rating Potential
The updated analyst price target for Coloplast has been reduced by DKK 6.53. This change reflects a slight reset in fair value as analysts incorporate higher discount rates, marginally softer margin assumptions, and recent price target cuts, along with mixed rating changes across the Street.Mise à jour du récit • Mar 26
COLO B: New CEO Appointment And Reset P/E Will Support Future Re Rating
Coloplast's analyst fair value target has been trimmed from DKK 579.78 to DKK 567.16, as analysts factor in slightly lower long term growth, modestly softer margin assumptions and small adjustments to future P/E expectations following a mix of recent target cuts and one upgrade. Analyst Commentary Recent research on Coloplast has been mixed, with several target cuts alongside one upgrade.Mise à jour du récit • Mar 11
COLO B: Reset P/E And New Leadership Will Support Future Re Rating
The updated analyst price target for Coloplast has been trimmed by around DKK 9 to reflect lower Street targets. This includes cuts to DKK 504 at Deutsche Bank and reductions at RBC Capital, JPMorgan and Berenberg, as analysts factor in slightly higher discount rates, modestly softer margin assumptions and a lower future P/E multiple.Mise à jour du récit • Feb 25
COLO B: Reset P/E And Dividend Will Support Future Re Rating
Analysts have trimmed their DKK price targets on Coloplast, reflected in a lower fair value estimate from DKK 615 to DKK 588, as they factor in slightly more cautious assumptions on growth, margins and future P/E multiples following recent target reductions from several research houses. Analyst Commentary Bullish Takeaways Bullish analysts still see room for upside from current levels, even with reduced DKK price targets.Mise à jour du récit • Feb 10
COLO B: Reset P/E And Dividend Will Support Future Upside
Analysts have trimmed their fair value estimate for Coloplast from DKK 678.22 to DKK 615.06, reflecting recent price target cuts and updated assumptions on the discount rate, revenue growth, profit margins and future P/E multiples. Analyst Commentary Recent Street research on Coloplast has focused on recalibrating expectations rather than fundamentally changing the story.Article d’analyse • Jan 25
Coloplast A/S' (CPH:COLO B) P/E Is On The Mark
Coloplast A/S' ( CPH:COLO B ) price-to-earnings (or "P/E") ratio of 33.6x might make it look like a strong sell right...Mise à jour du récit • Jan 24
COLO B: Dividend Reliability And Premium P/E Will Support Future Upside
Analysts have lowered their Coloplast price targets by DKK 10, to a range of DKK 535 to DKK 640, reflecting slightly lower fair value assumptions, modestly softer revenue growth expectations, and a marginally reduced future P/E multiple. Analyst Commentary Recent research updates on Coloplast point to a tighter valuation range, with price targets now clustered between DKK 535 and DKK 640.Mise à jour du récit • Jan 09
COLO B: Sustained Margins And Dividend Payouts Will Support Future Upside
Narrative update The analyst price target for Coloplast has edged up by about DKK 0.30 to reflect slightly higher fair value estimates. Recent Street research shows a mix of views, with some analysts lifting targets toward DKK 535 and others resetting them closer to DKK 640, which has led to modest adjustments to discount rate, revenue growth, profit margin, and future P/E assumptions.Mise à jour du récit • Dec 13
COLO B: Sustained Margin Strength Will Support Upside As Dividend Payouts Increase
Analysts have nudged our Coloplast fair value estimate slightly higher to about DKK 689 per share from roughly DKK 689 previously, reflecting a modest uptick in long term multiple assumptions even as recent Street price target revisions have moved in mixed directions. Analyst Commentary Recent Street actions on Coloplast highlight a divided view on near term upside versus longer term execution and growth.Article d’analyse • Dec 04
Coloplast (CPH:COLO B) Is Increasing Its Dividend To DKK18.00
Coloplast A/S ( CPH:COLO B ) has announced that it will be increasing its dividend from last year's comparable payment...Mise à jour du récit • Nov 29
COLO B: Sustained Margin Strength Will Support Upside Amid Market Challenges
Coloplast’s analyst fair value estimate was revised slightly upward to DKK 688.67 from DKK 685.39. Analysts weighed recent price target changes along with minor adjustments to growth expectations and profit margins.Article d’analyse • Nov 20
Coloplast (CPH:COLO B) Will Pay A Larger Dividend Than Last Year At DKK18.00
Coloplast A/S ( CPH:COLO B ) will increase its dividend from last year's comparable payment on the 9th of December to...Mise à jour du récit • Nov 14
COLO B: Future Execution In Core Markets Will Drive Share Price Momentum
The analyst consensus price target for Coloplast has modestly decreased. Updated projections reflect cautious sentiment from analysts, who cite modest adjustments to growth and profitability expectations.Mise à jour du récit • Oct 31
COLO B: Executive Team Changes And Chronic Care Strategy Will Drive Outperformance
Coloplast’s analyst price target was reduced slightly from DKK 691.83 to DKK 686.00, as analysts cite modestly lower revenue growth expectations and recent target decreases across several major firms. Analyst Commentary Recent commentary from market analysts highlights a balanced perspective on Coloplast’s outlook, with both raised and lowered price targets reflecting shifting sentiment in key performance areas.Mise à jour du récit • Oct 17
Chronic Care Focus And Emerging Markets Will Redefine Healthcare
Coloplast's analyst price target has been reduced by nearly DKK 10 to DKK 691.83. Analysts cite mixed recent revisions in target prices, reflecting a balanced outlook amid evolving growth and margin expectations.Mise à jour du récit • Oct 03
Chronic Care Focus And Emerging Markets Will Redefine Healthcare
Coloplast's analyst price target has been revised downward from DKK 716 to DKK 701. Analysts have adjusted their expectations in response to a series of recent target reductions following tempered growth and margin forecasts.Mise à jour du récit • Aug 30
Chronic Care Focus And Emerging Markets Will Redefine Healthcare
Coloplast’s consensus price target was modestly reduced to DKK718.06 as analysts weighed concerns about slowing revenue growth and margin pressure against stable demand in key product portfolios and longer-term benefits from innovation and expansion. Analyst Commentary Bearish analysts cite concerns over slowing revenue growth and margin pressure, particularly in core European markets.Article d’analyse • Aug 22
Coloplast A/S Just Missed EPS By 16%: Here's What Analysts Think Will Happen Next
It's been a good week for Coloplast A/S ( CPH:COLO B ) shareholders, because the company has just released its latest...
Nouveau récit • Nov 07
Operational Efficiencies And Innovations In Urology And Wound Care Propel Future Growth
Improved operational efficiency and strategic expansions are expected to enhance net margins and earnings over the long term.Rendement pour les actionnaires
| COLO B | DK Medical Equipment | DK Marché | |
|---|---|---|---|
| 7D | 1.3% | -0.06% | -0.05% |
| 1Y | -29.6% | -17.7% | -1.4% |
Rendement vs Industrie: COLO B a sous-performé le secteur Danish Medical Equipment qui a rapporté -17.7 % au cours de l'année écoulée.
Rendement vs marché: COLO B a sous-performé le marché Danish qui a rapporté -1.4 % au cours de l'année écoulée.
Volatilité des prix
| COLO B volatility | |
|---|---|
| COLO B Average Weekly Movement | 3.9% |
| Medical Equipment Industry Average Movement | 3.9% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in DK Market | 7.6% |
| 10% least volatile stocks in DK Market | 2.4% |
Cours de l'action stable: COLO B n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché Danish.
Volatilité au fil du temps: La volatilité hebdomadaire de COLO B ( 4% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1954 | 17,213 | Gavin Wood | www.coloplast.com |
Coloplast A/S développe et vend des produits et des services de soins intimes au Danemark, aux États-Unis, au Royaume-Uni, en France et dans le monde entier. La société opère à travers les segments Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, et Advanced Wound Care. Elle fournit des produits de soins pour stomies, notamment SenSura Mio, qui s'adapte aux formes corporelles individuelles et offre une discrétion optimale pour divers types de stomies, et SenSura Ostomy care solutions, ainsi que des accessoires pour stomies sous la marque Brava.
Coloplast A/S Résumé des fondamentaux
| COLO B statistiques fondamentales | |
|---|---|
| Capitalisation boursière | DKK 98.13b |
| Bénéfices(TTM) | DKK 2.76b |
| Recettes(TTM) | DKK 28.44b |
35.5x
Ratio P/E3.5x
Ratio P/SLe site COLO B est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| COLO B compte de résultat (TTM) | |
|---|---|
| Recettes | DKK 28.44b |
| Coût des recettes | DKK 9.32b |
| Marge brute | DKK 19.12b |
| Autres dépenses | DKK 16.36b |
| Les revenus | DKK 2.76b |
Derniers bénéfices déclarés
Jun 30, 2026
Prochaine date de publication des résultats
Nov 03, 2026
| Résultat par action (EPS) | 12.27 |
| Marge brute | 67.23% |
| Marge bénéficiaire nette | 9.71% |
| Ratio dettes/capitaux propres | 170.8% |
Quelles ont été les performances à long terme de COLO B?
Voir les performances historiques et les comparaisonsDividendes
5.3%
Rendement actuel des dividendes188%
Ratio de distributionAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/08/20 12:04 |
| Cours de l'action en fin de journée | 2026/08/20 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/09/30 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Coloplast A/S est couverte par 42 analystes. 20 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Hassan Al-Wakeel | Barclays |
| Robert Bate | Barclays |